Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Date:9/17/2009

    YM Enrolls First Patients in Multinational Randomized, Double-Blind Brain
    Metastases Trial

MISSISSAUGA, Sept. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico. YM BioSciences also announced that it has enrolled the first two patients in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from non-small-cell lung cancer (NSCLC).

"Mexico is the 21st country to have approved nimotuzumab for marketing and, while YM's license for major market territories for nimotuzumab does not include Mexico, this approval reflects the growing recognition throughout much of the world of the value to patients of our drug and the progress being made in its commercialization," said David Allan, Chairman and CEO of YM BioSciences. "As part of YM's registration strategy for nimotuzumab, we were also pleased to report the opening of this second of two randomized, double-blind trials that YM is conducting in Canada and which are both now being expanded internationally."

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and developed at the Center of Molecular Immunology in Cuba. Nimotuzumab is approved in two of the countries in YM's territories. The drug has demonstrated efficacy in clinical trials without producing the numerous and severe toxicities observed with the other marketed EGFR-targeting drugs. Mexican regulatory authorities have approved nimotuzumab for the treat
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
5. Cell Biosciences Signs Agreement to Acquire Alpha Innotech
6. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
7. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
10. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
11. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... 20, 2014 PureTech , a science ... healthcare problems, announced today the closing of a ... from Invesco Perpetual, a $120 Billion group of ... PureTech,s existing pipeline forward and to advance new ... scientific creativity to really go for the big ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... - MacoPharma increased its forecast for P-Capt(R) filters sale in 2008;, - Use of affinity prion adsorbent for ... in excess of $25 M over the next 5 years ... - $4 M in 2008;,- 10th product approved by the FDA and or the EMEA, contributing ... growth., MONTREAL, ...
... Cholesterol Test Can Help Identify Patients At Risk of Heart ... ... Atherotech, Inc., a,cardio-diagnostic company, today announced that the largest private,insurers in ... (FEHB) Program now cover the VAP (Vertical Auto Profile),Test, the most ...
... Software Platform Further Solidifies Netsmart as Leader in Behavioral Healthcare ... ... Florida, GREAT RIVER, N.Y., Feb. 6 Netsmart Technologies, Inc.,a ... organizations, today announced it has signed a contract to,provide comprehensive licensed ...
Cached Biology Technology:ProMetic provides business update - Over $35 million worth of business secured in January 2ProMetic provides business update - Over $35 million worth of business secured in January 3ProMetic provides business update - Over $35 million worth of business secured in January 4VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3
(Date:10/18/2014)... 2,000 patients referred for evaluation of suspected genetic ... for 25 percent, including detection of a number ... to disease, according to a study appearing in ... to coincide with the American Society of Human ... exons or coding regions of thousands of genes ...
(Date:10/17/2014)... German . Why ... order to reproduce? And why are there two sexes anyway? ... issue of the research journal Molecular Human Reproduction ... from Bielefeld University Bielefeld has compiled this special issue on ... female to copulate with several males in quick succession – ...
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... Food and Drug Administration (FDA) has granted approval to ... Alza Corporation's Duragesic Patch (Fentanyl Transdermal System) used to ... be managed with alternative analgesics. When applied to the ... medication that is slowly absorbed into the body through ...
... found that introducing a growth factor protein into a mouth ... according to a new paper in the February issue of ... sizeable mouth wound, replacing a tooth takes more than simply ... to anchor the new tooth in place. Such reconstructive surgery ...
... protein called IRE1, which helps stressed-out cells make new ... believed. A new study by researchers from the University ... Institute reveals the surprising finding that this same signaling ... called B lymphocytes. , "This is a unique signaling ...
Cached Biology News:Gene therapy promising for growing tooth-supporting bone 2Gene therapy promising for growing tooth-supporting bone 3Multi-purpose protein regulates new protein synthesis and immune cell development 2Multi-purpose protein regulates new protein synthesis and immune cell development 3
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
... offers the most comprehensive, cost-effective solution ... have incorporated unprecedented quality into both ... includes proven detection chemistries and antibodies ... TechMate protocol. It also includes our ...
Human Cell Line Slides...
Mouse Cell Line Slides...
Biology Products: